Stock Track | Mind Medicine (MindMed) Soars 5.28% Following H.C. Wainwright's Buy Rating Reiteration

Stock Track11-12

Shares of Mind Medicine (MindMed) Inc. (MNMD) surged 5.28% in intraday trading on Tuesday, following a bullish report from H.C. Wainwright. The biotech company, known for its work in psychedelic-inspired medicines, saw its stock climb as investors responded positively to the reaffirmed analyst confidence.

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine before the market opened, maintaining a price target of $55.00. This target suggests significant upside potential from the stock's current trading levels, likely contributing to the renewed investor interest and subsequent price jump.

The reiterated Buy rating and the ambitious price target underscore H.C. Wainwright's continued optimism about Mind Medicine's prospects in the burgeoning field of psychedelic medicine. As the company progresses with its research and development efforts, such positive analyst sentiment could play a crucial role in shaping investor perceptions and driving stock performance in the competitive biotech sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191839451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191839451","market":"sg","top_or_hot":-1,"title":"Stock Track | Mind Medicine (MindMed) Soars 5.28% Following H.C. Wainwright's Buy Rating Reiteration","media":"Stock Track","content":"<p>Shares of Mind Medicine (MindMed) Inc. (MNMD) surged 5.28% in intraday trading on Tuesday, following a bullish report from H.C. Wainwright. The biotech company, known for its work in psychedelic-inspired medicines, saw its stock climb as investors responded positively to the reaffirmed analyst confidence.</p>\n\n<p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine before the market opened, maintaining a price target of $55.00. This target suggests significant upside potential from the stock's current trading levels, likely contributing to the renewed investor interest and subsequent price jump.</p>\n\n<p>The reiterated Buy rating and the ambitious price target underscore H.C. Wainwright's continued optimism about Mind Medicine's prospects in the burgeoning field of psychedelic medicine. As the company progresses with its research and development efforts, such positive analyst sentiment could play a crucial role in shaping investor perceptions and driving stock performance in the competitive biotech sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mind Medicine (MindMed) Soars 5.28% Following H.C. Wainwright's Buy Rating Reiteration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mind Medicine (MindMed) Soars 5.28% Following H.C. Wainwright's Buy Rating Reiteration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Mind Medicine (MindMed) Inc. (MNMD) surged 5.28% in intraday trading on Tuesday, following a bullish report from H.C. Wainwright. The biotech company, known for its work in psychedelic-inspired medicines, saw its stock climb as investors responded positively to the reaffirmed analyst confidence.</p>\n\n<p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine before the market opened, maintaining a price target of $55.00. This target suggests significant upside potential from the stock's current trading levels, likely contributing to the renewed investor interest and subsequent price jump.</p>\n\n<p>The reiterated Buy rating and the ambitious price target underscore H.C. Wainwright's continued optimism about Mind Medicine's prospects in the burgeoning field of psychedelic medicine. As the company progresses with its research and development efforts, such positive analyst sentiment could play a crucial role in shaping investor perceptions and driving stock performance in the competitive biotech sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNMD","symbol_name":"Mind Medicine (MindMed) Inc.","start_time":0,"source_url":"","article_id":"1191839451","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191839451","pubTimestamp":1762887626,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Mind Medicine (MindMed) Inc. (MNMD) surged 5.28% in intraday trading on Tuesday, following a bullish report from H.C. Wainwright. The biotech company, known for its work in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNMD":"Mind Medicine (MindMed) Inc."},"translate_title":"股票追踪|Mind Medicine(MindMed)跟随H.C.飙升5.28%温赖特重申买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":1},"content_text":"Shares of Mind Medicine (MindMed) Inc. (MNMD) surged 5.28% in intraday trading on Tuesday, following a bullish report from H.C. Wainwright. The biotech company, known for its work in psychedelic-inspired medicines, saw its stock climb as investors responded positively to the reaffirmed analyst confidence.\nH.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine before the market opened, maintaining a price target of $55.00. This target suggests significant upside potential from the stock's current trading levels, likely contributing to the renewed investor interest and subsequent price jump.\nThe reiterated Buy rating and the ambitious price target underscore H.C. Wainwright's continued optimism about Mind Medicine's prospects in the burgeoning field of psychedelic medicine. As the company progresses with its research and development efforts, such positive analyst sentiment could play a crucial role in shaping investor perceptions and driving stock performance in the competitive biotech sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191839451","isCrawlerRequest":true}